The MONARCH study series enrolled patients with hormone receptor positive, ErbB2-negative advanced breast cancer and led to FDA approval of abemaciclib as initial endocrine-based therapy in combination with an aromatase inhibitor [75]. This evidence concerns the gene NR4A1 and breast cancer.